Alex J Fauer1,2, Matthew A Davis3,4, Sung Won Choi5,6, Lauren P Wallner5,6, Christopher R Friese3,5,7. 1. School of Nursing, University of Michigan, Ann Arbor, MI, USA. ajfau@umich.edu. 2. Center for Improving Patient and Population Health, University of Michigan, Ann Arbor, MI, USA. ajfau@umich.edu. 3. School of Nursing, University of Michigan, Ann Arbor, MI, USA. 4. Center for Improving Patient and Population Health, University of Michigan, Ann Arbor, MI, USA. 5. Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. 6. Medical School, University of Michigan, Ann Arbor, MI, USA. 7. School of Public Health, Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Gabapentinoid use for long-term cancer pain control may be problematic, given unclear mechanisms of action and increased concerns for physical dependence. The purpose of this report is to examine trends of gabapentinoid use among US adults with cancer from 2005 to 2015. METHODS: We conducted a serial, cross-sectional study using data from the Medical Expenditure Panel Survey (MEPS). We performed multiple logistic regression to examine the annual percentages of gabapentinoid users, which were adjusted for age, sex, and US region of residence. The amount of gabapentinoid prescriptions filled in 2015 was also estimated. RESULTS: The adjusted percentage of gabapentinoid users in 2015 was 5.60% (3.79%, 7.41%), 2.39 times greater than the percentage in 2005 (p < .001). By 2015, the number of gabapentinoid prescriptions had grown to approximately 3.52 million (2.40 million, 4.65 million). CONCLUSION: We observed greater than a twofold increase in the trend of gabapentinoid medication use among US adults with cancer. Investigations on the long-term efficacy of gabapentinoids for complex pain syndromes, and mitigation of risks, is essential to guide informed clinical management and keep patients safe.
BACKGROUND: Gabapentinoid use for long-term cancer pain control may be problematic, given unclear mechanisms of action and increased concerns for physical dependence. The purpose of this report is to examine trends of gabapentinoid use among US adults with cancer from 2005 to 2015. METHODS: We conducted a serial, cross-sectional study using data from the Medical Expenditure Panel Survey (MEPS). We performed multiple logistic regression to examine the annual percentages of gabapentinoid users, which were adjusted for age, sex, and US region of residence. The amount of gabapentinoid prescriptions filled in 2015 was also estimated. RESULTS: The adjusted percentage of gabapentinoid users in 2015 was 5.60% (3.79%, 7.41%), 2.39 times greater than the percentage in 2005 (p < .001). By 2015, the number of gabapentinoid prescriptions had grown to approximately 3.52 million (2.40 million, 4.65 million). CONCLUSION: We observed greater than a twofold increase in the trend of gabapentinoid medication use among US adults with cancer. Investigations on the long-term efficacy of gabapentinoids for complex pain syndromes, and mitigation of risks, is essential to guide informed clinical management and keep patients safe.
Entities:
Keywords:
Cancer; Gabapentin; Practice pattern; Supportive care
Authors: A Deljou; S J Hedrick; E R Portner; D R Schroeder; W M Hooten; J Sprung; T N Weingarten Journal: Br J Anaesth Date: 2018-02-10 Impact factor: 9.166
Authors: Arya Shah; E Matthew Hoffman; Michelle L Mauermann; Charles L Loprinzi; Anthony J Windebank; Christopher J Klein; Nathan P Staff Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-08 Impact factor: 10.154
Authors: Su Jeong Song; Ji Min; Sung Yun Suh; Sun Hoi Jung; Hyeon Joo Hahn; Seock-Ah Im; Ju-Yeun Lee Journal: Support Care Cancer Date: 2017-02-16 Impact factor: 3.603
Authors: Shivani Shinde; Pamela Gordon; Prashant Sharma; James Gross; Mellar P Davis Journal: Support Care Cancer Date: 2014-08-29 Impact factor: 3.603
Authors: Gery P Guy; Kun Zhang; Michele K Bohm; Jan Losby; Brian Lewis; Randall Young; Louise B Murphy; Deborah Dowell Journal: MMWR Morb Mortal Wkly Rep Date: 2017-07-07 Impact factor: 17.586
Authors: Christopher R Friese; Alex J Fauer; Clare Kuisell; Kari Mendelsohn-Victor; Nathan C Wright; Jennifer J Griggs; Milisa Manojlovich Journal: Health Serv Res Date: 2020-10-30 Impact factor: 3.402